Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.155 USD | +1.78% | -0.49% | -36.23% |
May. 15 | HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating | MT |
May. 14 | Transcript : Fennec Pharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.23% | 192M | |
+8.38% | 115B | |
+10.13% | 105B | |
-11.69% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.00% | 16.01B | |
+2.28% | 14.14B | |
+20.54% | 10.71B |
- Stock Market
- Equities
- FENC Stock
- News Fennec Pharmaceuticals Inc.
- Fennec Pharmaceuticals Brief: Fennec Pharmaceuticals and Norgine Over the Weekend Entered into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand